Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-06-30FDA Approved: ONDANSETRON — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approves a supplemental application for ondansetron from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This action suppo…
-
FDA approval · 2013-06-30FDA Approved: ONDANSETRON — Supplemental Application (JVET PHARMACEUTICALS LLC)
FDA approved a supplemental application for ondansetron submitted by JVET PHARMACEUTICALS LLC. This action updates the approval for this gen…
-
FDA approval · 2013-06-29FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for ondansetron submitted by PAI Holdings, LLC dba PAI Pharma.
-
CLINICAL_TRIALS trial_result · 2013-05-24Clinical Trial Update: Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation [EARLY_Phase 1]
This early-phase study reports preliminary data on the efficacy and safety of combining aprepitant with ondansetron and dexamethasone to pre…
-
FDA approval · 2013-04-26FDA Approved: ONDANSETRON — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Ondansetron from Sun Pharmaceutical Industries, Inc. (ANDA077557).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-04-03FDA Approved: ONDANSETRON — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for ondansetron filed by Hikma Pharmaceuticals USA Inc., a supplemental approval for the generic ant…
-
FDA approval · 2013-03-27FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC.
-
FDA approval · 2013-03-27FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approves a supplemental application for EMEND (fosaprepitant dimeglumine) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2013-03-20FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC. The action relates to the approved anti…
-
FDA approval · 2013-03-19FDA Approved: ONDANSETRON — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for ondansetron from Hikma Pharmaceuticals USA Inc., confirming approval of a generic ondansetron pr…
-
FDA approval · 2013-02-22FDA Approved: ONDANSETRON HYDROCHLORIDE — Original Application (Baxter Healthcare Corporation)
The FDA approved Baxter Healthcare Corporation's original ANDA for ondansetron hydrochloride, enabling a generic version of ondansetron to b…
-
FDA approval · 2013-02-14FDA Approved: GRANISETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Granisetron (granisetron hydrochloride) from Fresenius Kabi USA, LLC.
-
FDA approval · 2013-02-14FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron).
-
CLINICAL_TRIALS trial_result · 2012-12-31Clinical Trial Update: Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting [Phase 4]
Phase 4 trial update reports on the efficacy and safety of palonosetron hydrochloride for preventing chemotherapy-induced nausea and vomitin…
-
FDA approval · 2012-12-21FDA Approved: ONDANSETRON — Original Application (Eugia US LLC)
FDA approved the original application for ondansetron hydrochloride by Eugia US LLC. The generic drug is indicated to prevent nausea and vom…
-
FDA approval · 2012-12-21FDA Approved: ONDANSETRON — Original Application (Eugia US LLC)
FDA approves Eugia US LLC's original application for ondansetron hydrochloride, granting generic approval for this antiemetic under the ANDA…
-
CLINICAL_TRIALS trial_result · 2012-12-13Clinical Trial Update: Treatment of Chemotherapy-induced Nausea and Vomiting [Phase 2]
A Phase 2 trial evaluating treatment for chemotherapy-induced nausea and vomiting has completed. The provided snippet does not include trial…
-
CLINICAL_TRIALS trial_result · 2012-12-06Clinical Trial Update: Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting [Phase 3]
Phase 3 trial evaluating stimulation of an auricular acupuncture point for chemotherapy-induced nausea and vomiting in cancer patients has c…
-
CLINICAL_TRIALS trial_result · 2012-10-05Clinical Trial Update: Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
A re-examination study of EMEND (aprepitant) completed, with results posted in 2012 evaluating prevention of chemotherapy-induced nausea and…
-
CLINICAL_TRIALS trial_result · 2012-09-25Clinical Trial Update: Phase II Proof-of-concept Study of APD421 [Phase 2]
A Phase II proof-of-concept study of APD421 for chemotherapy-induced nausea and vomiting has completed.
-
FDA approval · 2012-09-24FDA Approved: APREPITANT — Original Application (Sandoz Inc)
The FDA approved Sandoz Inc's original ANDA for aprepitant, a generic NK1 receptor antagonist, for the prevention of chemotherapy-induced na…
-
FDA approval · 2012-09-10FDA Approved: METOCLOPRAMIDE — Supplemental Application (Genus Lifesciences Inc.)
The FDA approved a supplemental application for metoclopramide hydrochloride from Genus Lifesciences Inc., completing regulatory action for …
-
CLINICAL_TRIALS trial_result · 2012-09-10Clinical Trial Update: Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting [Phase 3]
A Phase 3 trial evaluating intravenous and oral casopitant for prevention of chemotherapy-induced nausea and vomiting has completed.
-
CLINICAL_TRIALS trial_result · 2012-08-17Clinical Trial Update: Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy) [Phase 4]
Phase 4 study evaluating the efficacy and safety of the Sancuso transdermal granisetron patch for preventing chemotherapy-induced nausea and…
-
CLINICAL_TRIALS trial_result · 2012-06-28Clinical Trial Update: Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy [Phase 3]
Phase 3 trial assessing whether continuing dexamethasone after emetogenic chemotherapy improves quality of life in cancer patients; the stud…